Jean-Luc Vachiéry, Catharina Brlge, Bjorn Cools, An Damen, Fabian Demeure, Michel De Pauw, Céline Dewachter, Daniel De Wolf, Laurence Gabriel, Laurent Godinas, Julien Guiot, Steven Haine, Mathias Leys, Marc Meysman, Anne-Catherine-Pouleur, Davis Ruttens, Els Vansteenkiste, Wendy Vansteenkiste, Thierry Weber, Gil Wirtz, Marion Delcroix
Hôpital Universitaire de Bruxelles Erasme. University Hospitals of Leuven and University of Leuven. Belgische Patiëntenvereniging voor Pulmonale Hypertensie. Université catholique de Louvain. Ghent University Hospital. Brussels University Hospital. University Hospital of Liège and University of Liège. Antwerp University. AZ Groeninge. Universitair Ziekenhuis Brussel. Cliniques universitaires Saint-Luc. Ziekenhuis Oost-Limburg. Hasselt University. Hôpital de la Citadelle. Centre Hospitalier de Luxembourg.
Belgium and Luxembourg
Acta Cardiologica
Acta Cardiol 2024;
DOI: 10.1080/00015385.2024.2408130
Abstract
Pulmonary arterial hypertension (PAH) is a rare disease affecting the small pulmonary vessels, ultimately leading to right ventricular failure and death. Current treatment options target three different pathways (endothelin, nitric oxide/cGMP and prostacyclin pathways). Despite their demonstrated efficacy, these therapies (commonly used in combination) do not cure the disease which is why novel pathways beyond the traditional ‘big three’ are being developed. Sotatercept is a ligand trap for multiple proteins within the TGF-β superfamily that was recently approved in the US for the treatment of PAH. Unlike currently available therapies, sotatercept has the potential to act as an anti-remodelling agent rather than a vasodilator. The safety and efficacy of subcutaneous (SC) sotatercept have been established in two multicentre, placebo-controlled randomised-controlled trials. The compound has been shown to consistently improve a variety of measurable endpoints, including exercise capacity, haemodynamics, quality of life and delay of clinical worsening. The drug appears to have an acceptable safety profile, although it is associated with an increased risk in developing telangiectasia and biological changes affecting platelet counts and haemoglobin. This study reviews the current evidence on SC sotatercept and provides a Belgian perspective on its place in the future treatment strategy for PAH.
Category
Review Articles Concerning Pulmonary Vascular Disease
Medical Therapy. Efficacy or Lack of Efficacy
Medical Therapy. Adverse Effects or Lack of Adverse Effects
Age Focus: Adult Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: No